Quest Diagnostics (DGX) Stock Forecast & Price Target

$164.19 +2.87 (+1.78%)

(As of 11/21/2024 ET)

Quest Diagnostics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
8

Buy
6

Based on 14 Wall Street analysts who have issued ratings for Quest Diagnostics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 8 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for DGX.

Consensus Price Target

$164.58
0.24% Upside

According to the 14 analysts' twelve-month price targets for Quest Diagnostics, the average price target is $164.58. The highest price target for DGX is $185.00, while the lowest price target for DGX is $135.00. The average price target represents a forecasted upside of 0.24% from the current price of $164.19.

Get the Latest News and Ratings for DGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Quest Diagnostics and its competitors.

DGX Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	1 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$164.58	$154.92	$150.58	$146.09
Forecasted Upside	0.24% Upside	-1.62% Downside	-1.94% Downside	7.62% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Hold

Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

DGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Quest Diagnostics Stock vs. The Competition

Type	Quest Diagnostics	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	0.24% Upside	26,677.73% Upside	8.51% Upside
News Sentiment Rating	Positive News See Recent DGX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/28/2024	Piper Sandler 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$150.00 ➝ $165.00	+5.85%
10/24/2024	Mizuho 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$160.00 ➝ $174.00	+10.74%
10/23/2024	Baird R W 0 of 5 stars	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
10/23/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$165.00 ➝ $166.00	+6.52%
10/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$154.00 ➝ $168.00	+6.69%
10/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$165.00 ➝ $185.00	+17.48%
Get the Latest News and Ratings for DGX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.
10/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$157.00 ➝ $182.00	+15.58%
10/7/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$158.00 ➝ $165.00	+9.42%
8/28/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	In-Line	$165.00	+7.38%
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$152.00 ➝ $155.00	+11.64%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$135.00	+6.23%
2/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$140.00 ➝ $155.00	+22.76%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$140.00 ➝ $160.00	+16.82%
8/3/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$145.00	+6.35%
2/3/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight	$135.00 ➝ $140.00	-0.44%
1/25/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$143.00 ➝ $146.00	+0.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:42 AM ET.

DGX Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Quest Diagnostics is $164.58, with a high forecast of $185.00 and a low forecast of $135.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 8 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DGX shares.
: According to analysts, Quest Diagnostics's stock has a predicted upside of 0.24% based on their 12-month stock forecasts.
: Over the previous 90 days, Quest Diagnostics's stock had 2 upgrades by analysts.
: Quest Diagnostics has been rated by research analysts at Baird R W, Barclays, Citigroup, Evercore ISI, Mizuho, Piper Sandler, Robert W. Baird, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Quest Diagnostics less than other "medical" companies. The consensus rating score for Quest Diagnostics is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how DGX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Let’s be blunt (Ad)

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now

This page (NYSE:DGX) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Stock Forecast & Price Target